Pancreatic Cancer Research

ResearcherJiangnan UniversityActive in the last 2 years

Enhong Chen

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 7 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers
2 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2025: 2 papers

Papers 2

  1. NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4-acetylated LAMB3-mediated FAK/ERK pathway. Co-author DOI 10.1002/cac2.70045↗
  2. Targeting the ac4C 'Writer' NAT10 enhances pancreatic cancer immunotherapy via dual modulation of CD8+ T cells and tumor cells. First author DOI 10.1038/s41419-025-08156-0↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shuo Zhang · 2 shared papers, 2025 · strength 0.45
  2. Leisheng Wang · 2 shared papers, 2025 · strength 0.45
  3. Hao Hu · 2 shared papers, 2025 · strength 0.45
  4. Shudong Hu · 1 shared paper, 2025 · strength 0.22
  5. Hao Ye · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.